Nirmal Bang

Nirmal Bang, one of the leading stock broking companies in India, caters to retail and institutional clients by offering them a range of financial products and services, including equities, derivatives, commodities, currency derivatives, mutual funds, IPOs, insurance, depository services and PMS.

Nirmal Bang is drawn from a diversity of professional backgrounds, and blend of experience, skill and dedication is shared with its clients. Nirmal Bang emphasizes adequate, thorough research local and world-wide developments, balancing these with the astute discovery of intrinsic values, synergies and growth. The aim is simply to help the investors to maximize their returns.

A Relationship Beyond Broking

External broker reports(aggregated public sources), Nirmal Bang

External broker reports(aggregated public sources)

Equity Bottom-Up

Navin Fluorine International / Equity Bottom-Up

<div><div><div><div><ul><li>4QFY22 performance update: Revenue performance came in line with our estimate, wherein legacy business and high-value business grew by 29% and 19% YoY, respectively.</li></ul><div><div><div><div><ul><li>Near term margin weakness; but has levers in place to improve the same sustainably</li></ul><div><div><div><div><ul><li>Why we are bullish on CRAMS segment? The share of fluorine-containing small molecules in the innovators’ pipeline is significantly higher at ~45% (vis-à-vis 29% share in the novel drug approvals).</li></ul></div></div></div></div></div></div></div></div></div></div></div></div><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

4QFY22 performance update: Revenue performance came in line with our estimate, wherein legacy business and high-value business grew by 29% and 19% YoY, respectively.Near term margin weakness; but has levers in place to improve the same sustainablyWhy we are bullish on CRAMS segment? The share of fluorine-containing small molecules in the innovators’ pipeline is significantly higher at ~45% (vis-à-vis 29% share in the novel drug approvals).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Navin Fluorine International - Consistent Order Wins from MNCs - Sign of a Solid Franchise